STERIS Stock Forecast, Price & News

STERIS (NYSE:STE) Frequently Asked Questions

Is STERIS a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STERIS stock.
View analyst ratings for STERIS or view top-rated stocks.

How has STERIS's stock price been impacted by Coronavirus (COVID-19)?

STERIS's stock was trading at $145.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, STE shares have increased by 55.2% and is now trading at $225.49.
View which stocks have been most impacted by COVID-19.

When is STERIS's next earnings date?

STERIS is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for STERIS.

How were STERIS's earnings last quarter?

STERIS plc (NYSE:STE) released its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported $1.99 EPS for the quarter, beating the Zacks' consensus estimate of $1.82 by $0.17. The medical equipment provider earned $1.20 billion during the quarter, compared to analyst estimates of $1.16 billion. STERIS had a trailing twelve-month return on equity of 12.44% and a net margin of 6.50%. During the same period in the prior year, the business posted $1.48 EPS.
View STERIS's earnings history.

How often does STERIS pay dividends? What is the dividend yield for STERIS?

STERIS declared a quarterly dividend on Thursday, October 28th. Stockholders of record on Tuesday, November 23rd will be paid a dividend of $0.43 per share on Friday, December 17th. This represents a $1.72 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Monday, November 22nd.
View STERIS's dividend history.

Is STERIS a good dividend stock?

STERIS pays an annual dividend of $1.72 per share and currently has a dividend yield of 0.78%. STERIS has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of STERIS is 61.43%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, STERIS will have a dividend payout ratio of 19.84% next year. This indicates that STERIS will be able to sustain or increase its dividend.
View STERIS's dividend history.

What guidance has STERIS issued on next quarter's earnings?

STERIS updated its FY 2022 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $7.600-$7.850 for the period, compared to the Thomson Reuters consensus estimate of $7.720. The company issued revenue guidance of -.

What price target have analysts set for STE?

6 Wall Street analysts have issued 12 month price targets for STERIS's shares. Their forecasts range from $233.00 to $270.00. On average, they anticipate STERIS's share price to reach $248.80 in the next year. This suggests a possible upside of 10.3% from the stock's current price.
View analysts' price targets for STERIS or view top-rated stocks among Wall Street analysts.

Who are STERIS's key executives?

STERIS's management team includes the following people:

• Daniel A. Carestio, President, Chief Executive Officer & Director
• Michael Joseph Tokich, Chief Financial Officer & Senior Vice President
• Kathleen Lynn Bardwell, Chief Compliance Officer & Senior Vice President
• John Adam Zangerle, Secretary, Senior Vice President & General Counsel
• Renato G. Tamaro, Treasurer & Vice President

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?

196 employees have rated STERIS CEO Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among STERIS's employees.

Who are some of STERIS's key competitors?

Some companies that are related to STERIS include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Masimo (MASI) and Teleflex (TFX).
View all of STE's competitors.

What other stocks do shareholders of STERIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).

What is STERIS's stock symbol?

STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."

Who are STERIS's major shareholders?

STERIS's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.69%), WCM Investment Management LLC (6.83%), Massachusetts Financial Services Co. MA (4.30%), Generation Investment Management LLP (3.13%), Janus Henderson Group PLC (2.89%) and Geode Capital Management LLC (1.85%). Company insiders that own STERIS stock include Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden and Walter M Rosebrough Jr.
View institutional ownership trends for STERIS.

Which institutional investors are selling STERIS stock?

STE stock was sold by a variety of institutional investors in the last quarter, including Alta Capital Management LLC, Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., Retirement Systems of Alabama, Morgan Stanley, Schroder Investment Management Group, Renaissance Technologies LLC, and BlackRock Inc.. Company insiders that have sold STERIS company stock in the last year include Cary L Majors, Cynthia L Feldmann, Jacqueline B Kosecoff, Julia Madsen, Michael J Tokich, and Renato Tamaro.
View insider buying and selling activity for STERIS or view top insider-selling stocks.

Which institutional investors are buying STERIS stock?

STE stock was purchased by a variety of institutional investors in the last quarter, including Balyasny Asset Management LLC, Principal Financial Group Inc., Alliancebernstein L.P., Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., Strs Ohio, Polar Capital Holdings Plc, and Geode Capital Management LLC.
View insider buying and selling activity for STERIS or or view top insider-buying stocks.

How do I buy shares of STERIS?

Shares of STE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STERIS's stock price today?

One share of STE stock can currently be purchased for approximately $225.49.

How much money does STERIS make?

STERIS has a market capitalization of $22.55 billion and generates $3.11 billion in revenue each year. The medical equipment provider earns $397.40 million in net income (profit) each year or $2.80 on an earnings per share basis.

How many employees does STERIS have?

STERIS employs 13,000 workers across the globe.

When was STERIS founded?

STERIS was founded in 1987.

What is STERIS's official website?

The official website for STERIS is www.steris.com.

Where are STERIS's headquarters?

STERIS is headquartered at 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296.

How can I contact STERIS?

STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The medical equipment provider can be reached via phone at (531) 232-2000, via email at [email protected], or via fax at 440-639-4457.